Clinical trials: Vaginal Atrophy
Vaginal Atrophy
Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.
Primary: Evaluation of improved vaginal moisture in postmenopausal women. Secondary: the improvement of symptoms resulting from the dryness Rating (VHI), evaluation of the decrease in vaginal pH, assessment of Sexual Function…
- Trial name
- NCT02571127
- Testing
- Hidra1
- Volunteers
- 46 people
- Sponsor
- Farmoquimica S.A.
Vaginal Dryness
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal…
- Trial name
- NCT02638337
- Testing
- Ospemifene
- Volunteers
- 631 people
- Sponsor
- Shionogi
Vaginal Dryness, Breast Cancer
Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients
This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months.
- Conditions
- Vaginal Dryness, Breast Cancer, Vulvovaginal Atrophy
- Trial name
- RF-Vaginale (NCT06900374)
- Testing
- GynWave-360, Local hydratation
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Centre Oscar Lambret
Vulvo Vaginal Atrophy, Genitourinary Syndrome of Menopause (GSM)
Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment
This is a randomized, controlled trial aiming to evaluate the effectiveness of adding vaginal dilators to the treatment of vulvovaginal atrophy.
- Conditions
- Vulvo Vaginal Atrophy, Genitourinary Syndrome of Menopause (GSM), Vaginal Atrophy in Breast Cancer Patients, Vaginal Atrophy Patients With GSM
- Trial name
- NCT06828640
- Testing
- vaginal dilators
- Where
- Belgium
- Volunteers
- 160 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Vaginal Atrophy, Sexual Dysfunction
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.
- Conditions
- Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness
- Trial name
- NCT03178825
- Testing
- Hybrid Fractional Laser
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sciton
Vulvar Atrophy, Breast Cancer
Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors
VAGINAL PRASTERONE in the treatment of VAGINAL ATROPHY IN PATIENTS WITH BREAST CANCER TREATMENT WITH AROMATASE INHIBITORS (VIBRA STUDY)
- Conditions
- Vulvar Atrophy, Breast Cancer, Genitourinary Syndrome of Menopause
- Trial name
- VIBRA (NCT04705883)
- Testing
- Prasterone (DHEA), Micronized
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Clinic of Barcelona
Vaginal Atrophy, Genitourinary Disease
Effect of Hybrid Laser 10600+1540 nm on GSM
The primary objective of the study is to clinically confirm, by comparison with a control group, the performance of the 10600 +1540 nm laser in the improvement of atrophic vaginal epithelium at 3 months after the last laser…
- Trial name
- NCT03956563
- Testing
- Youlaser MT Group 2, Youlaser MT Group 1
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Quanta System, S.p.A.
Vulvovaginal Atrophy, Genitourinary Symptoms and Ill-Defined Conditions
Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients
To determine the efficacy of ablative carbon dioxide laser in the treatment of the signs and symptoms of vulvovaginal atrophy (VVA) or genitourinary syndrome of menopause (GSM) in women with breast cancer.
- Trial name
- LAAVA2 (NCT03628092)
- Testing
- CO2 Fractional Ablative Laser
- Where
- 2 sites in Australia
- Volunteers
- 70 people
- Sponsor
- Royal North Shore Hospital
Vaginal Atrophy, Atrophic Vaginitis
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment.
- Conditions
- Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)
- Trial name
- ASSIST-VLA (NCT07346287)
- Testing
- 7-940
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stratpharma AG
Vulvar and Vaginal Atrophy
Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy
The objectives of this study are to evaluate the therapeutic equivalence of the Test formulation, Estradiol Vaginal Cream 0.01% (Prasco, LLC) to the marketed product, Estrace® Cream (estradiol vaginal cream, 0.01%) in patients…
- Trial name
- NCT03332303
- Testing
- Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream
- Where
- 27 sites in United States
- Volunteers
- 540 people
- Sponsor
- Prasco LLC
Vulvovaginal Atrophy, Dyspareunia
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene daily for twenty weeks.
- Trial name
- NCT02784613
- Testing
- Ospemifene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sue Goldstein
Pelvic Organ Prolapse, Vaginal Atrophy
The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse
The purpose of this study is to find out how long it takes the vagina to respond to hormonal vaginal cream in women with pelvic organ prolapse (bulge in the vagina).
- Trial name
- NCT00803335
- Testing
- Vaginal conjugated estrogen cream 0.5gm, Vaginal conjugated estrogen cream 1.0gm
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- TriHealth Inc.
Menopause, Genitourinary Syndrome of Menopause
Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy
Tissues of the genitals of women are both androgen (testosterone) and estrogen dependent. The clitoris, vestibule, urethra, anterior vaginal wall, peri-urethral tissue, and pelvic floor all depend on androgens for normal…
- Conditions
- Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome
- Trial name
- NCT03782480
- Testing
- Intrarosa
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Center for Vulvovaginal Disorders
Vaginal Atrophy
Real-world Evidence Study on the Performance and Safety of Halova Ovules
An open-label, multicentric, non-randomized, single-arm, pilot, interventional clinical investigation to confirm the tolerability and performance of the medical device Halova in lubrication of the vagina and vaginal atrophy…
- Trial name
- NCT05654610
- Testing
- Halova
- Where
- 14 sites in Romania
- Volunteers
- 249 people
- Sponsor
- Perfect Care Distribution
Menopause
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health
This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in…
- Trial name
- MPS (NCT04001088)
- Testing
- Probiotic
- Where
- 5 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Vulvo Vaginal Atrophy
Clinical Investigation to Assess Safety and Efficacy of INNEA AQUA in Adult Women With Vulvo-Vaginal Atrophy (VVA)
Clinical investigation to assess safety and efficacy of INNEA AQUA in adult women with Vulvo-Vaginal Atrophy (VVA). To assess the Safety and efficacy of INNEA AQUA
- Trial name
- NCT07367061
- Testing
- product: Innea Aqua vaginal use, arm 2: standard of care
- Where
- 3 sites in Romania
- Volunteers
- 62 people
- Sponsor
- Innate srl
Primary Sjögren Syndrome
Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions
A total of 68 women with pSS and 135 healthy female patients were included in the study. All women in the study and control groups were evaluated gynecologically, and genital findings during the examination and variables related…
- Trial name
- NCT04816370
- Testing
- FSFI
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ankara Education and Research Hospital
Menopause, Postmenopausal Vaginal Atrophy
Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency
This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.
- Trial name
- NCT01507454
- Testing
- estradiol, 25 mcg
- Where
- Germany
- Volunteers
- 1,613 people
- Sponsor
- Novo Nordisk A/S
Vaginal Atrophy, Genitourinary Syndrome of Menopause
The Efficacy of Topical Vaginal Oxytocin Gel in Postmenopausal Women With Vulvovaginal Atrophy
A Phase three randomized, double-blinded, study to asses the efficacy and safety of oxytocin gel in postmenopausal women with vaginal atrophy due to Genitourinary Syndrome of Menopause GSM.
- Conditions
- Vaginal Atrophy, Genitourinary Syndrome of Menopause, Vulvar Atrophy
- Trial name
- NCT06514586
- Testing
- Oxytocin, Hydroxypropyl methylcellulose
- Where
- Egypt
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Oxagon
Lower Urinary Tract Symptoms, Female Genitourinary Disease
Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women
The goal of this clinical trial is to evaluate whether vaginal 17β-estradiol effectively treats storage symptoms of lower urinary tract symptoms (LUTS) and enhances quality of life.
- Conditions
- Lower Urinary Tract Symptoms, Female Genitourinary Disease, Urinary Stress Incontinence, Urinary Urge Incontinence
- Trial name
- NCT06508944
- Testing
- vaginal 17 beta-estradiol, Behavioral modifications
- Where
- Thailand
- Volunteers
- 86 people
- Sponsor
- Mahidol University